Naltrexone Side Effects
Naltrexone at 50 mg daily does NOT cause weight gain; it is actually associated with weight loss, particularly in women, though the effect is modest. 1
Common Side Effects
The most frequently reported adverse effects of naltrexone 50 mg daily include:
- Nausea (10%) - the most common side effect 1
- Headache (7%)
- Dizziness (4%)
- Nervousness and anxiety (4%)
- Fatigue (4%)
- Insomnia (3%)
- Vomiting (3%)
- Abdominal pain/cramps
- Joint and muscle pain
These effects typically occur early in treatment and are often transient 1.
Weight Effects - Key Point
Naltrexone is associated with weight LOSS, not weight gain. In controlled studies:
- Women experienced significant weight loss of approximately 1.7 kg over 8 weeks 2
- Men did not show significant weight changes 2
- When combined with bupropion (naltrexone-bupropion ER), it produces moderate weight loss and is FDA-approved for obesity management 3
The mechanism involves modulation of hedonic eating and anorexigenic effects through opioid receptor antagonism 3.
Serious but Less Common Side Effects
Hepatotoxicity
Monitor liver function carefully. At doses 5-fold higher than standard (300 mg/day), naltrexone caused hepatocellular injury in 19% of patients 1. At standard 50 mg doses, liver effects are less common but still warrant monitoring, especially in patients with pre-existing liver disease 1.
Psychiatric Effects
- Depression (0-15% incidence, similar to placebo at 0-17%) 1
- Suicidal ideation (0-1%, similar to placebo at 0-3%) 1
- No causal relationship established, but monitoring is essential 1
Cardiovascular
- Modest increases in blood pressure, particularly in first 8 weeks 3
- Monitor vital signs periodically 3
Critical Contraindications and Warnings
Absolute contraindication: Patients requiring opioid therapy. Naltrexone will:
- Block opioid analgesic efficacy
- Precipitate severe withdrawal in opioid-dependent patients 3, 1
- Must discontinue before procedures requiring opioids (e.g., endoscopy with fentanyl) 3
Opioid-free period required: Minimum 7-10 days for short-acting opioids; up to 2 weeks for buprenorphine or methadone 1.
Special Consideration: Interaction with Agomelatine
While the evidence provided does not specifically address naltrexone-agomelatine interactions, both medications have hepatic considerations:
- Agomelatine carries significant hepatotoxicity risk 4
- Combined use requires vigilant liver function monitoring
- Consider baseline and periodic liver enzyme testing (ALT, AST)
Nausea Management Strategy
Nausea risk factors include: 5
- Younger age
- Female gender
- Shorter abstinence duration (in alcohol use disorder)
- Lighter drinking history (paradoxically)
Mitigation approaches:
- Start with 25 mg daily for first week, then increase to 50 mg 1
- Longer abstinence periods before initiation reduce nausea risk 5
- Take with food (though not specified in label)
- Gradual titration improves tolerability
Monitoring Requirements
Essential monitoring includes:
- Liver function tests at baseline and periodically (especially given agomelatine co-administration)
- Blood pressure and heart rate, particularly in first 12 weeks 3
- Psychiatric symptoms, including mood changes and suicidal ideation 1
- Weight (expect modest loss, not gain)
Clinical Pearls
- Discontinuation rates: 25% discontinued due to adverse effects versus 10% with placebo 3
- Most common reasons for stopping: nausea (4.6-9.6%), vomiting (0.7-2%), headache (0.9-1.8%) 3
- Effects are generally mild and transient when they occur 1
- The drug is considered safe at standard doses in opioid-free individuals 1